echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Recombinant new coronavirus vaccine (CHO cells) is approved for emergency use | Transformation Highlights

    Recombinant new coronavirus vaccine (CHO cells) is approved for emergency use | Transformation Highlights

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, with the strong support of all sectors of society and the joint efforts of all scientific researchers, the Chinese Academy of Sciences has continuously produced scientific and technological achievements, and continued to transfer and transform the achievements to serve the main battlefield of the national economy.

    In order to further enhance the public's understanding of the highlights of the Chinese Academy of Sciences, and at the same time to promote the various units of the Academy to further strengthen the dissemination and promotion of the transfer and transformation of achievements, the activity of "Selecting the Highlights of the Transfer and Transformation of Scientific and Technological Achievements of the Chinese Academy of Sciences" was launched.

    The relevant functional departments of the Chinese Academy of Sciences have now recommended candidate entries, and everyone is welcome to actively participate in the voting.
    The relevant votes will be used as an important reference for the officially elected entries.

    Thank you for your encouragement and support to the scientific and technological innovation work of the Chinese Academy of Sciences! The candidate entry "Recombinant Novel Coronavirus Vaccine (CHO Cell) Emergency Use Approved" is recommended today.
    Please click "Read the original text" to vote.

    Completion unit: Institute of Microbiology, Chinese Academy of Sciences, etc.
    On March 10, 2021, the recombinant novel coronavirus vaccine (CHO cell) jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilongkoma Biopharmaceutical Co.
    , Ltd.
    was approved for emergency use in China , Becoming the fourth domestic new coronavirus vaccine approved for emergency use, and the first international new coronavirus recombinant subunit protein vaccine approved for clinical use.

    The vaccine has completed Phase I and Phase II clinical trials in October 2020.

    The results showed that after the whole course of vaccination of the vaccine, no serious adverse reactions occurred, which conformed to the characteristics of small adverse reactions of subunit vaccines, and the level of neutralizing antibodies produced was equivalent to the current international recombinant protein vaccines and mRNA new crown vaccines, reaching the international advanced level.

    The vaccine will start phase III clinical trials in China, Uzbekistan, Pakistan, Ecuador, and Indonesia starting from November 2020, with 29,000 patients planned to be vaccinated.

    The Phase III clinical trial is currently progressing smoothly, and Uzbekistan, the country where the first trial was initiated, has been approved for registration.

    The vaccine production uses engineered cells (CHO) to produce recombinant proteins, and does not require high-grade biosafety laboratory production workshops.
    The production process is stable and reliable.
    Large-scale industrial production at home and abroad can be quickly realized, significantly reducing vaccine production costs and storage.
    And convenient transportation.

    At present, Anhui Zhifeilongkoma Biopharmaceutical Co.
    , Ltd.
    has built a production line with an annual output of 300 million doses of new crown vaccine, which is equivalent to meeting 100 million people inoculation.

    Recombinant Novel Coronavirus Vaccine (CHO Cell) Support & Voting, please click to read the original source: Chinese Academy of Sciences website
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.